However, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and β-blockers are the first-line to prevent dilated cardiomyopathy in dystrophinopathy patients. The gene discussed is ACE; the disease is neuromuscular disease caused by qualitative or quantitative defects of dystrophin.